Cannabis Law Report

OCTOBER 1, 2021

Virpax recently acquired global rights to VRP324, a product candidate for the intranasal delivery of a pharmaceutical-grade Schedule V cannabidiol (CBD) for the management of epilepsy in children, a rare pediatric disease. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the 16 years.

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Chronic Pain 52

SMPL

MAY 26, 2020

Alas, Mr. Gardner wrote in 2005, that would require access to expensive testing equipment. fast-tracked clinical trials of GW Pharmaceuticals’ 98 percent CBD drug, Epidiolex. There haven’t been enough clinical trials and there never will be,” said Mr. Clarke, the cannabis seed collector.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40

Cannabis Law Report

NOVEMBER 24, 2021

Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Refractory paediatric epilepsy. Conclusions. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ).

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Lancet Neurol Dec 23 2015. Fabricio A.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73